Yamana Keita, Kawasaki Riku, Kondo Kousuke, Hirano Hidetoshi, Kawamura Shogo, Sanada Yu, Bando Kaori, Tabata Anri, Azuma Hideki, Takata Takushi, Sakurai Yoshinori, Tanaka Hiroki, Kodama Tomoki, Kawamoto Seiji, Nagasaki Takeshi, Ikeda Atsushi
Program of Applied Chemistry, Graduate School of Advanced Science and Engineering 1-4-1 Kagamiyama Higashi-Hiroshima City 739-8527 Japan
Institute for Integrated Radiation and Nuclear Science, Kyoto University 2, Asahiro-Nishi, Kumatori-cho, Sennan-gun Osaka 590-0494 Japan.
Nanoscale Adv. 2023 Jun 1;5(15):3857-3861. doi: 10.1039/d3na00028a. eCollection 2023 Jul 25.
The development of boron agents with integrated functionality, including biocompatibility, high boron content, and cancer cell targeting, is desired to exploit the therapeutic efficacy of boron neutron capture therapy (BNCT). Here, we report the therapeutic efficacy of BNCT using a HER-2-targeted antibody-conjugated boron nitride nanotube/β-1,3-glucan complex. The anticancer effect of BNCT using our system was 30-fold that of the clinically available boron agent l-BPA/fructose complex.
为了利用硼中子俘获疗法（BNCT）的治疗效果，人们期望开发具有综合功能的硼剂，包括生物相容性、高硼含量和癌细胞靶向性。在此，我们报告了使用HER-2靶向抗体偶联的氮化硼纳米管/β-1,3-葡聚糖复合物进行BNCT的治疗效果。使用我们的系统进行BNCT的抗癌效果是临床可用硼剂l-BPA/果糖复合物的30倍。
Zotero 插件
